Welcome to our dedicated page for TNL Mediagene SEC filings (Ticker: TNMG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TNL Mediagene (TNMG) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as a foreign private issuer listed on The Nasdaq Capital Market. TNL Mediagene files reports on Form 6-K under the Securities Exchange Act of 1934, furnishing press releases, transaction documents and corporate updates that explain key developments in its digital media and data business.
Recent Form 6-K filings include explanations of Nasdaq listing status and compliance with the minimum bid price rule, details of a 1-for-20 share consolidation of ordinary shares, and descriptions of financing arrangements such as senior convertible notes and an equity line of credit. Other filings furnish press releases related to unaudited financial results, annual general meeting outcomes, amendments to corporate documents, and information about board changes and director appointments.
For investors analyzing TNL Mediagene’s capital structure, these filings outline terms of convertible notes, warrants and equity purchase agreements, as well as the company’s interactions with the Nasdaq Hearings Panel. They also incorporate press releases that describe operational initiatives, including AI-driven content infrastructure, content licensing partnerships and business unit performance, giving additional context to the company’s strategic direction.
On Stock Titan, each filing is accompanied by AI-powered summaries designed to highlight the main points of long-form documents, helping readers quickly understand what a particular Form 6-K covers and why it may matter for TNMG stock. Users can monitor new filings as they are retrieved from EDGAR, review historical disclosures, and connect regulatory information with the company’s broader narrative in digital media, advertising technology and e-commerce.
TNL Mediagene has regained compliance with Nasdaq’s minimum bid price requirement, allowing its shares to remain listed on the Nasdaq Capital Market. Nasdaq confirmed that the company met Listing Rule 5550(a)(2) after the closing bid price of its ordinary shares stayed at $1.00 per share or higher for fifteen consecutive trading days from December 23, 2025 to January 14, 2026.
At the same time, Nasdaq’s Hearings Panel imposed a one-year Discretionary Panel Monitor starting January 20, 2026. During this period, if the company fails any continued listing standard, it will not receive extra time or a cure period; instead, Nasdaq staff will issue a delisting determination, though the company may request a new hearing.
TNL Mediagene reports that a Nasdaq Hearings Panel has granted its request to continue listing on The Nasdaq Capital Market, provided it regains compliance with Nasdaq’s $1 Bid Price Rule (Listing Rule 5550(a)(2)) on or before January 7, 2026. During this exception period, the company must promptly report any significant events that could affect compliance, and the Panel may reconsider the exception if circumstances make continued listing inadvisable.
The decision follows a December 16, 2025 hearing, requested after Nasdaq staff issued a determination on November 6, 2025 to delist the company’s securities for failing to regain bid-price compliance after a 180‑day period. TNL Mediagene presented a compliance plan that includes a reverse share split, and its shares will continue trading on Nasdaq while the Panel issues a final written decision after January 7, 2026.
TNL Mediagene reports changes to its convertible financing arrangements and a new funding tranche. The company previously issued a senior convertible note with an aggregate principal amount of $4,722,222 and has fully repaid this Initial Note on November 11, 2025. On December 8, 2025, TNL Mediagene amended its existing securities purchase agreement with 3i, LP to revise key terms for future senior convertible notes, including maturity, installment payments, optional prepayment, and acceleration mechanics.
On the same date, the company issued a new senior convertible note to the investor with a principal amount of $1,666,667 (reflecting a $1,500,000 funding amount with a 10% original issue discount). In connection with this Second Note, TNL Mediagene also issued a five-year warrant to purchase its ordinary shares, with an exercise price set at 125% of the initial conversion price of the Second Note, exercisable for cash when a resale registration is effective or on a cashless basis otherwise.
TNL Mediagene submitted a Form 6-K describing its 2025 Annual General Meeting of Shareholders held on December 2, 2025. The company states that it issued a press release on December 5, 2025 announcing the meeting results.
The filing also notes that shareholders approved an amended and restated memorandum and articles of association, which are included as an exhibit. The report is signed on behalf of TNL Mediagene by Chief Executive Officer Tzu-Wei Chung on December 5, 2025.
TNL Mediagene reported it received a Nasdaq staff determination letter stating it did not regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share by November 3, 2025, and is not eligible for a second 180-day grace period.
The letter has no immediate effect on the company’s Nasdaq Capital Market listing. The company intends to request a hearing, which will automatically stay any suspension or delisting action pending the hearing and any extension granted. Under Nasdaq rules, a Hearing Panel may grant an extension not to exceed 180 days from the date of the determination letter.
TNL Mediagene filed a Form 6-K announcing it will hold its Annual General Meeting of Shareholders on November 25, 2025.
The filing furnishes proxy materials, including Exhibit 99.1 (Notice of Annual General Meeting of Shareholders and Proxy Statement), Exhibit 99.2 (Notice Regarding the Availability of Proxy Materials), and Exhibit 99.3 (Form of Proxy Card).
TNL Mediagene filed an amended Form 6-K to update a previously furnished report. The amendment applies only to Exhibit 99.1, which is an amended press release dated September 17, 2025. The company states this change is solely to remove references to certain company names and that no other changes have been made to the original report.
TNL Mediagene filed a Form 6-K describing a third amendment to its equity line of credit ordinary share purchase agreement with Tumim Stone Capital LLC, originally dated November 25, 2024. The amendment, signed on September 14, 2025, changes how Tumim’s purchases of TNL Mediagene ordinary shares are valued.
The company can now choose to have its ordinary shares priced over either a one-trading-day or a three-trading-day valuation period, based on the market price and/or trading volume of the shares. The amendment also makes related changes to the maximum purchase amount and purchase price Tumim will use when buying shares under the equity line arrangement.
FAQ
What is the current stock price of TNL Mediagene (TNMG)?
What is the market cap of TNL Mediagene (TNMG)?
